Suven Life Sciences Limited has announced a board meeting scheduled for January 29, 2026, to review and approve the company's third-quarter financial performance for FY26. The pharmaceutical company issued the formal notice on January 22, 2026, in compliance with regulatory requirements.

Board Meeting Details

The meeting will be conducted at the company's registered office located at SDE Serene Chambers, 6th Floor, Road No 5, Banjara Hills, Hyderabad–500034. The board will consider and approve the unaudited financial results for both standalone and consolidated operations.

Trading Window Restrictions

In accordance with the company's Prevention of Insider Trading (PIT) Code, Suven Life Sciences has implemented trading restrictions for designated persons and their relatives. The trading window closure became effective from January 1, 2026, and will continue until 48 hours after the declaration of the financial results.

This measure ensures compliance with SEBI regulations regarding insider trading and maintains market integrity during the period leading up to the results announcement.

Regulatory Compliance

The board meeting notice has been issued pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has duly informed both the BSE Limited and National Stock Exchange of India Limited about the scheduled meeting.

Shrenik Soni, Company Secretary & Compliance Officer, signed the official notice, ensuring all regulatory protocols are followed for the upcoming financial results disclosure.

Suven Life Sciences has achieved a significant milestone by completing 100% patient enrollment for its Phase-2B trial of Ropanicant in Major Depressive Disorder (MDD), more than two months ahead of schedule. The clinical-stage biopharmaceutical company successfully enrolled 195 patients across 35 sites in the USA within six months of study initiation.

Trial Design and Enrollment Achievement

The Phase-2B study represents a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Ropanicant compared to placebo in patients with MDD. The trial measures improvements in depression symptoms using the Montgomery-Asberg Depression Rating Scale (MADRS) over a six-week treatment duration.

Timeline and Expected Results

With patient enrollment now complete, Suven Life Sciences expects the last patient out (LPO) by the end of February 2026. The company anticipates topline efficacy and safety results by May 2026. Safety data from the ongoing study continues to be monitored, with no significant concerns observed to date.

Management Commentary

Venkat Jasti, Chairman and Managing Director of Suven Life Sciences, expressed gratitude to patients, caregivers, investigators, and the clinical development team for their exceptional commitment in achieving this milestone rapidly. He emphasized that this collective progress moves the company closer to delivering new therapeutic options that can meaningfully improve patient lives.

Dr. Ramakrishna Nirogi, President and CSO, highlighted that reaching 100% patient enrollment approximately six months from study initiation reflects high interest from patients and physicians in a potential treatment option with a novel mechanism of action.

About Ropanicant

Ropanicant (SUVN-911) is a novel, selective nicotinic α4β2 receptor antagonist in development for MDD. The drug candidate has demonstrated strong efficacy in animal models of depression and may address key limitations of current treatments, including rapid onset of action, reduced sexual dysfunction, and enhanced cognitive function. The Phase-2a trial previously demonstrated a favorable safety profile and significant improvements in depressive symptoms as measured by the MADRS score.